3′-Azido-3′-deoxy-5′-O-isonicotinoylthymidine: A novel antiretroviral analog of zidovudine. II. Stability in aqueous media and experimental and theoretical ionization constants

Nucleosides, Nucleotides and Nucleic Acids

Volumn 22, Issue 9, 2003, Pages 1789-1803

  Teijeiro, Silvina A ^a   Raviolo, Mónica A ^a   Motura, Marisa I ^a   Briñón, Margarita C ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

Antiretroviral; PKa; Stability; Zidovudine analogs

Indexed keywords

3' AZIDO 3' DEOXY 5' O ISONICOTINOYLTHYMIDINE; ANTIRETROVIRUS AGENT; BUFFER; DRUG ANALOG; ISONICOTINIC ACID; UNCLASSIFIED DRUG; ZIDOVUDINE; 3'-AZIDO-3'-DEOXY-5'-O-ISONICOTINOYLTHYMIDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; WATER;

ANALYTIC METHOD; ARTICLE; DRUG DEGRADATION; DRUG STABILITY; DRUG STRUCTURE; IONIZATION; PKA; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; CHEMICAL STRUCTURE; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KINETICS; METHODOLOGY;

ANTI-HIV AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ISONICOTINIC ACIDS; KINETICS; MOLECULAR STRUCTURE; WATER; ZIDOVUDINE;

EID: 0141453763     PISSN: 15257770     EISSN: None     Source Type: Journal    
DOI: 10.1081/NCN-120023273     Document Type: Article

References (39)

1. Mitsuya, H.; Weinhold, K.J.; Furman, P.A.; St Clair, M.H.; Lehrman, S.N. ; Gallo, R.C.; Bolognesi, D.; Barry, D.W.; Broder, S. 3′-Azido-3′ -deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 7096-7100.
2. Fischl, M.A.; Richman, D.D.; Grieco, M.H.; Gottlieb, M.S.; Volberding, P.A.; Laskin, O.L.; Leedom, J.M.; Groopman, J.E.; Mildvan, D.; Schooley, R.T.; Jackson, G.G.; Durack, D.T.; King, D. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 1987, 317, 185-191.
3. Yarchoan, R.; Mitsuya, H.; Myers, C.E.; Broder, S. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N. Engl. J. Med. 1989, 321, 726-738.
4. Richman, D.D.; Fischl, M.A, Grieco, M.H.; Gottlieb, M.S.; Volberding, P.A.; Laskin, O.L.; Leedom, J.M.; Groopman, J.E.; Mildvan, D.; Hirsch, M.S.; Jackson, G.G.; Durack, D.T.; Nusinoff-Lehrman, S.N. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 1987, 317, 192-197.
5. Fletcher, C.V.; Collier, A.C. Principles and management of human immunodeficiency virus infection. In Pharmacotherapy. A Pathophysiologic Approach, 3rd Ed.; Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M., Eds.; Appleton & Lange, 1997; 2361-2363.
6. De Clercq, E. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491-2517.
7. De Clercq, E. Reverse transcriptase inhibitors as anti-HIV drugs. In Antiviral Against AIDS; Unger, R.E., Kreuter, J., Röbsamen-Waigmann, H., Eds.; Marcel Dekker: New York, 2000; 107-150.
8. Darbyshire, J. Therapeutic interventions in HIV infection - a critical view. Trop. Med. Int. Health 2000, 5, A26-A31.
9. Kukhanova, M.; Krayevsky, A.; Prusoff, W.; Cheng, Y.C. Design of anti-HIV compounds: From nucleoside to nucleoside 5′-triphosphate analogs, problems and perspectives. Curr. Pharm. Des. 2000, 6, 585-598.
10. Tan, X.; Chu, C.K.; Boudinot, F.D. Development and optimization of anti-HIV nucleoside analogs and prodrugs: A review of their cellular pharmacology, structure-activity relationships and pharmacokinetics. Adv. Drug Deliv. Rev. 1999, 39, 117-151.
11. Parang, K.; Wiebe, L.I.; Knaus, E.E. Novel approaches for designing 5′-Oester prodrugs of 3′-azido-2′,3′-dideoxythymidine (AZT). Curr. Med. Chem. 2000, 7, 995-1039.
12. Motura, M.I.; Moroni, G.N.; Teijeiro, S.A.; Salomón, H.; Briñón, M.C. 3′-Azido-3′-deoxy-5′ -O-isonicotinoylthymidine, a new prodrug of zidovudine. synthesis, solid state characterization and anti-HIV-1 activity. Nucleos. Nucleot. Nucl. Acids. 2002, 21, 217-230.
13. Teijeiro, S.A.; Moroni, G.N.; Motura, M.I.; Briñón, M.C. Lipophilic character of pyrimidinic nucleoside derivatives: Correlation between shake flask, chromatographic (RP-TLC and RP-HPLC) and theoretical methods. J. Liq. Chrom. Rel. Technol. 2000, 23, 855-872.
14. Quevedo, M.A.; Moroni, G.N.; Briñón, M.C. Human serum albumin binding of novel antiretroviral nucleoside derivatives of AZT. Biochem. Biophys. Res. Comm. 2001, 288, 954-960.
15. Turk, G.; Moroni, G.N.; Pampuro, S.; Briñón, M.C.; Salomón, H. Antiretroviral activity and cytotoxicity of novel zidovudine (AZT) derivatives and the relation with their chemical structure. Int. J. Antimicrob. Agents 2002, 20, 282-288.
16. Connors, K.A.; Amidon, G.L.; Stella, V.J. Chemical Stability of Pharmaceuticals, 2nd Ed.; Wiley Sons: New York, 1968.
17. Cartensen, J.T.; Rhodes, C.T. Drug stability. In Principles and Practices, 3rd Ed.; Marcel Dekker: New York, 2000.
18. Wells, J.I. Pharmaceutical preformulation. In The Physicochemical Properties of Drug Substances; Ellis Horwood: New York, 1993; 13-20.
19. Jambhekar, S.S. Biopharmaceutical properties of drug substances. In Principles of Medicinal Chemistry, 4th Ed.; Foye, W.O., Lemke, T.L., Williams, D.A., Eds.; Williams and Wilkins: Baltimore, Philadelphia, 1995; 12-24.
20. Gringauz, A. Introduction to medicinal chemistry. In How Drugs Act and Why; Willey-VCH: New York, 1997; 1-6.
21. Good, S.S.; Reynolds, D.J.; Miranda, P. de. Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography. J. Chromatogr. 1988, 431, 123-133.
22. Mathes, L.E.; Muschik, G.; Demby, L.; Polas, P.; Mellini, D.W.; Issaq, H.J.; Sams, R. High-performance liquid chromatographic determination of 2′,3′-dideoxycytidine and 3′-azido-3′-deoxythymidine in plasma using a column-switching technique. J. Chromatogr. 1988, 432, 346-351.
23. Unadkat, J.D.; Crosby, S.S.; Wang, J.P.; Hertel, C.C. Simple and rapid high-performance liquid chromatographic assay for zidovudine (azidothymidine) in plasma and urine. J. Chromatogr. 1988, 430, 420-423.
24. Irth, H.; Tocklu, R.; Welten, K.; Jong, G.J. de; Brinkman, U.A.; Frei, R.W. Trace-level determination of 3′-azido-3′-deoxythymidine in human plasma by preconcentration on a silver (I)-thiol stationary phase with on-line reversed-phase high-performance liquid chromatography. J. Chromatogr. 1989, 491, 321-330.
25. Lacroix, C.; Hoang T.P.; Wojciechowski, F.; Duwoos, H.; Nouveau, J.; DiquetB. Simultaneous quantification of zidovudine and its metabolites in serum and urine by high-performance liquid chromatography using a column-switching technique. J. Chromatogr. 1990, 525, 240-245.
26. Stretcher, B.N.; Pesce, A.J.; Geisler, B.A.; Vine, W.H. A coupled HPLC/radioimmunoassay for analysis of zidovudine metabolites in mononuclear cells. J. Liq. Chromatogr. 1991, 14, 2261-2272.
27. Bolton, S. Pharmaceutical statistics. In Practical and Clinical Applications, 3rd Ed.; Marcel Dekker: New York, 1997; 216-264.
28. Morelli, B. "Zero-crossing" derivative spectrophotometric determination of mixtures of cephapirin sodium and cefuroxime sodium in pure form and in injections. Analyst 1988, 113, 1077-1082.
29. Morelli, B. Second-derivative spectrophotometric assay of mixtures of dicloxacillin sodium and ampicillin sodium in pharmaceuticals. J. Pharm. Sci. 1988, 77, 1042-1046.
30. Dabbene, V.G.; Briñón, M.C.; Bertorello, M.M. de. Stability determination of 3-bromo-2-hydroxy-N-(3,4-dimethyl-5-isoxazolyl)-1,4-naphthoquinon-4-imine in ethanol by first-derivative spectrophotometry. J. Pharm. Sci. 1994, 83, 1617-1621.
31. Dabbene, V.G.; Briñón, M.C.; Bertorello, M.M. de Determination of 3-chloro-N-chloro-N-(3,4-dimethyl-5-isoxazolyl)-4-amine-1,2-naphthoquinone in presence of its degradation products using second derivative spectrophotometry. Anal. Chim. Acta 1996, 318, 221-228.
32. Miller, J.N. Basic statistical methods for analytical chemistry. Part. 2. Calibration and regression methods. A Review. Analyst 1991, 116, 3-14.
33. Edwardson, P.A.; Bhaskar, G.; Fairbrother, J.E. Method validation in pharmaceutical analysis. J. Pharm. Biomed. Anal. 1990, 8, 929-933.
34. ACS Subcommittee on Environmental Analytical Chemistry, Guidelines for data acquisition and data quality evaluation in environmental chemistry. Anal. Chem., 1980, 52, 2242-2249.
35. Mehta, A.C. The validation criteria for analytical methods used in pharmacy practice research. J. Clin. Pharm. Ther. 1989, 14, 465-473.
36. a) Christensen, J.J., Rytting, J.H., Izatt, R.M., Thermodynamics of proton dissociation in dilute aqueous solution. VIII. pK, ΔH°, and ΔS° values for proton ionization from several pyrimidines and their nucleosides at 25°. J. Phys. Chem., 1967, 71, 2700-2705;
37. b) Christensen, J.J., Rytting, J.H., Izatt, R.M., Thermodynamics of proton dissociation in dilute aqueous solution. Part XIV. pK, ΔH° and ΔS° values for proton dissociation from several pyrimidines and their nucleosides at 10 and 40°C. J. Chem. Soc. B. Phys. Org. 1970, 1643-1646.
38. Perrin, D.D. Prediction of pKa values. In Physical Chemical Properties of Drugs; Yalkowsky, S.H., Sinkula, A.A., Valvani, S.C., Eds.; Marcel Dekker: New York, 1980; Vol. 10, 1-48.
39. Benet, L.Z.; Goyan, J.E. Potentiometric determination of dissociation constants. J. Pharm. Sci. 1967, 56, 665-680.